Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Diagnostic radiopharmaceuticals | 1 |
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
APP(Beta amyloid A4 protein) | 1 |
Target |
Mechanism APP modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date06 Apr 2012 |
Target |
Mechanism 30S subunit inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date08 Oct 1957 |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Feb 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Florbetapir F-18 ( APP ) | Glioblastoma More | Phase 2 |
NBQ-59 | Neoplasms More | Pending |
Tetracycline Hydrochloride ( 30S subunit ) | Rheumatoid Arthritis More | Pending |